Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 10/20 | 0.65 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 7/20 | 0.46 |
| ▸ | CSF1R | P07333 | 5/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21373447 | 1.00 | WEE1 (0.65) | WEE1JAK2SRCTNK2EGFR | |
| SCHEMBL29506559 | 0.95 | WEE1 (0.61) | WEE1TNK2 | |
| SCHEMBL21373398 | 0.95 | WEE1 (0.61) | WEE1TNK2 | |
| SCHEMBL21373336 | 0.95 | WEE1 (0.59) | WEE1JAK2SRCTNK2EGFR | |
| SCHEMBL29506445 | 0.95 | WEE1 (0.59) | WEE1JAK2SRCTNK2EGFR | |
| SCHEMBL21373312 | 0.95 | WEE1 (0.65) | WEE1JAK2SRCTNK2EGFR | |
| SCHEMBL29506507 | 0.95 | WEE1 (0.65) | WEE1JAK2SRCTNK2EGFR | |
| SCHEMBL21373452 | 0.94 | WEE1 (0.62) | WEE1TNK2AXL | |
| SCHEMBL29506450 | 0.94 | WEE1 (0.62) | WEE1TNK2AXL | |
| SCHEMBL21373275 | 0.93 | WEE1 (0.57) | WEE1JAK2SRCTNK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118338905-A | Use of Wee1 kinase inhibitors in the treatment of cancer | 上海瑛派药业有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-117202908-A | Use of Wee1 kinase inhibitors in the treatment of cancer diseases | 上海瑛派药业有限公司 | 2023-12-08 | — | — | CN | claimed |
| WO-2023093840-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-06-01 | — | — | WO | claimed |
| WO-2022188802-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2022-09-15 | — | — | WO | claimed |
| CN-109906227-B | 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones | 上海瑛派药业有限公司 | 2022-03-11 | — | — | CN | claimed |
| WO-2025074275-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS AND WEE1 INHIBITORS | REPARE THERAPEUTICS, INC. (CA) | 2025-04-10 | — | — | WO | disclosed |
| CN-118338905-A | Use of Wee1 kinase inhibitors in the treatment of cancer | 上海瑛派药业有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-3543242-B1 | 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2024-01-03 | — | — | EP | disclosed |
| CN-117202908-A | Use of Wee1 kinase inhibitors in the treatment of cancer diseases | 上海瑛派药业有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023093840-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-06-01 | — | — | WO | disclosed |
| WO-2022188802-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2022-09-15 | — | — | WO | disclosed |
| CN-109906227-B | 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones | 上海瑛派药业有限公司 | 2022-03-11 | — | — | CN | disclosed |